Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) announced on Wednesday the launch of its Nitazoxanide Tablets, 500 mg, the generic version of the reference listed drug Alinia.
Nitazoxanide is used to treat diarrhoea caused by certain parasites.
US annual sales for Nitazoxanide Tablets are approximately USD36.1m, based on the December 2024 moving annual total IQVIA data.
This launch expands ANI's portfolio and provides an alternative treatment option in the market.
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules
Dexcel Pharma's Nintedanib Capsules approved for US launch
Upsher-Smith launches generic version of Ciprodex ear drop suspension
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Breckenridge Pharmaceutical partners with sterile injectable manufacturer Maiva Pharma
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
Arna Pharma signs MOU with Slate Run Pharmaceuticals
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz